Avoid long-term continuous topical therapy; contact to eyes; large amounts & occlusion; contact w/ open wounds & mucous membranes; applying on the breast. Limit therapy to no more than 14 days at a time to minimise risk of developing resistance. May be associated w/ increased susceptibility to infection, aggravation of existing infection, & activation of latent infection. Contains cetostearyl alcohol & chlorocresol. Pregnancy. Childn. Fusidic acid: Reports of bacterial resistance. Betamethasone valerate: Always consider possible systemic absorption during treatment. Reports of visual disturbance. Risk of reversible hypothalamic-pituitary-adrenal (HPA) axis suppression following systemic absorption. Risk of atrophic changes on the face after prolonged treatment. Risk of raised IOP & glaucoma after use near the eyes, particularly w/ prolonged use & in patients predisposed to developing glaucoma.
Sign Out
